Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.48 USD
+0.02 (5.44%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.48 0.00 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
GRTS 0.48 +0.02(5.44%)
Will GRTS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GRTS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GRTS
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
Novavax (NVAX) Misses Q2 Earnings and Revenue Estimates
GRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
Other News for GRTS
Buy Rating Affirmed on Gritstone Oncology Amidst Promising GRANITE Program Milestones and Upcoming PFS Data Release
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)
Buy Rating Affirmed on Gritstone Oncology Amid Promising Trial Updates and Strong Financials
Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates